On October 20, 2026, the U.S. Food and Drug Administration posted Center for Drug Evaluation and Research warning letter 320-26-132 (MARCS-CMS 733231), dated September 29, 2026, to Baxter International Inc. The letter follows an inspection of Baxter Healthcare Corporation, FEI 1416980, at Round Lake, Illinois, from March 23 to April 2, 2026, and finds finished pharmaceuticals made there adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act because methods, facilities, or controls do not conform to 21 CFR parts 210 and 211. US manufacturers of sterile injectable drugs that produce cephalosporins and non-beta-lactam injectables in the same building, US contract manufacturers of finished sterile pharmaceuticals supplying hospitals, US distributors of cephalosporin and other sterile injectable finished drugs, and US hospital pharmacies and group purchasing organizations that buy Baxter injectable drugs must immediately review shared-facility beta-lactam separation, aseptic process simulation, visual inspection for visible particulates, and sterility and leak investigations against 21 CFR 211.42, 211.113, 211.160 and 211.192 before releasing sterile injectables for the US market, or products that do not conform to CGMP are adulterated under FD&C Act section 501(a)(2)(B) and FDA may seize them, seek an injunction, withhold export certificates, and withhold approval of new applications or supplements that list the site until the violations are corrected.
There is no fine. FDA found Baxter's April 23, 2026 response to the Form FDA 483 inadequate. A January 15, 2025 regulatory meeting had already covered similar CGMP violations at Round Lake.
- Authority: U.S. Food and Drug Administration, Center for Drug Evaluation and Research
- Entity: Baxter International Inc. (Baxter Healthcare Corporation, FEI 1416980, Round Lake, Illinois)
- Measure and amount: warning letter, no fine at this stage
- Legal basis: 21 CFR 211.42(c), 211.42(c)(10), 211.113(b), 211.160(b) and 211.192; FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
- Decision date: September 29, 2026, posted on the FDA warning-letter index on October 20, 2026
- Official source: FDA warning letter 320-26-132
What happened
CDER documented failed separation of cephalosporins from other injectables, media fills that missed worst-case conditions, visual inspection that missed particulates, and weak leak and sterility investigations. Cephalosporin has been detected on the non-beta-lactam side of a wall Baxter treated as sealed since January 2025. FDA states that no safe level of beta-lactam contamination has been determined to be a tolerable risk. On July 17, 2026 FDA recommended recall of cefazolin lot LD175708 after a May 9, 2025 cardboard finding, and Baxter agreed.
The breach
The letter cites 21 CFR 211.42(c), 211.42(c)(10), 211.113(b), 211.160(b) and 211.192. The operative sentence is quoted as written: "Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B)." On a 2025 cefazolin sterility failure, FDA says Baxter called the result a "no-test" without a Phase II investigation and released the lot in July 2025.
Who else is in the same regime
Every other US manufacturer that runs cephalosporins and non-beta-lactam injectables in one building, their contract manufacturers, US distributors of those finished drugs, and US hospital pharmacies and group purchasing organizations that buy Baxter injectables sit under the same CGMP parts.
What to check now
- Confirm cephalosporin and non-beta-lactam areas cannot share air, people or materials (21 CFR 211.42(c)), and trend hits since January 2025, including samples discarded since August 2024.
- Check media fills cover worst-case interventions and that biological-indicator runs do not accept routine survivors (21 CFR 211.113(b)).
- Requalify visual inspection for visible particulates (21 CFR 211.160(b)), including the May 9, 2025 cefazolin cardboard finding.
- Reopen the July 2025 cefazolin lot released after a "no-test" sterility result (21 CFR 211.192).
- Pharmacies and group purchasing organizations: match stock, including lot LD175708, to the July 17, 2026 recall.
Per-jurisdiction monitoring surfaces a CDER warning letter when FDA posts it.
